Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.23 (market cap $12.90B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is far larger — about 4.5× Dyne Therapeutics Inc. Common Stock's market cap, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days on average.
| DYN | EMB | |
|---|---|---|
Market Cap | $2.86B | $12.90B |
Volume | 3,341,579 | 8,768,615 |
Sector | Health | Fixed Income |
52-Week High | $26.78 | $97.74 |
52-Week Low | $14.60 | $90.14 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EMB trades at $91.26, up 0.2% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The stock faces resistance near $91-92 while support holds at $90. Recent corporate actions include scheduled dividend payments through October 2026, though key valuation metrics remain unavailable for fundamental assessment.
The outlook remains cautious given the bearish technical setup and limited fundamental visibility. Investment opportunity hinges on future financial disclosures, while risks include market volatility from rising bond yields and emerging market exposure. Analyst sentiment suggests EMB's returns will primarily come from yield rather than price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
